A practical reference on anti-doping: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-17. Anything still debated is marked as such rather than presented as settled.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
The Detroit Riverfront, for instance, is maintained and developed almost exclusively through nonprofit funding in partnership with public and private enterprises. This model for economic development and revitalization has seen enormous success in Detroit, with the Detroit Riverfront Conservancy raising in excess of $23 million to revitalize and maintain riverfront assets. This model for economic development is so promising that the city has turned to similar partnership strategies to manage, maintain, and revitalize several other city assets. Over the past seventy years, the city of Detroit has experienced a dramatic reduction in its population and economic well-being. This decline has left countless community members in economic turmoil, driving many residents to fall behind on taxes and subject their homes to tax foreclosure. Due to the overassessment of property values based on outdated appraisals, the property taxes on these homes are massively inflated, perpetuating further property foreclosure and community displacement. These foreclosed properties are often turned over to a public auction, where many of them are purchased by wealthy investors looking to take advantage of Detroit's housing market. Proponents of such investment argue that wealthy investors have minimized displacement by redeveloping vacant areas where people did not reside; however, this kind of investment can have additional repercussions beyond residents' physical and economic displacement.
Coalescent angiogenesis is a mode of angiogenesis, considered to be the opposite of intussusceptive angiogenesis, where capillaries fuse, or coalesce, to make a larger bloodvessel, thereby increasing blood flow and circulation. Coalescent angiogenesis has extended out of the domain of embryology. It is assumed to play a role in the formation of neovasculature, such as in a tumor.
Saturated fatty acids have no C=C double bonds. They have the formula CH3(CH2)nCOOH, where n is some positive integer. An important saturated fatty acid is stearic acid (n = 16), which when neutralized with sodium hydroxide is the most common form of soap.
=== Netherlands === In 2007, four food technology students in the Netherlands invented a powdered alcohol product called "Booz2go". They claimed that when mixed with water, the powder would produce a bubbly, lime-colored and lime-flavored drink, with 3% alcohol. When put into commercial production, it was expected to sell for €1.50 (approx. US$1.60) for a 20 gram sachet. The product's creators and marketers – Harm van Elderen, Martyn van Nierop, and others at Helicon Vocational Institute in Boxtel – claimed to be aiming at the youth market. They compared the drink to alcopops like Bacardi Breezer and said they expected the relatively low alcohol content would be popular with the young segment. Because of complexities in Dutch laws, powdered alcohol like Booz2Go would not be subject to the Alcohol and Horeca Code, because it is not literally an alcoholic drink. This means that anybody of any age could buy it legally. However, when dissolved in water, it would be subject to the Code, according to Director Wim van Dalen of the Dutch National Foundation for Alcohol Prevention. Von Dalen commented that while he generally did not support new alcoholic drinks, he doubted the powder would become attractive. A spokesman of the Ministry of Health, Welfare and Sport said they would not undertake any actions against the product, but added that the label would have to contain a warning about any health risks for the consumer, in accordance with other laws. In 2014, Booz2go is not yet commercially available.
==== Hypoglycemic unawareness ==== Recurrent episodes of hypoglycemia can lead to hypoglycemic unawareness, or the decreased ability to recognize hypoglycemia. As diabetics experience more episodes of hypoglycemia, the blood glucose level which triggers symptoms of hypoglycemia decreases. In other words, people without hypoglycemic unawareness experience symptoms of hypoglycemia at a blood glucose of about 55 mg/dL (3.0 mmol/L). Those with hypoglycemic unawareness experience the symptoms of hypoglycemia at far lower levels of blood glucose. This is dangerous for a number of reasons. The hypoglycemic person not only gains awareness of hypoglycemia at very low blood glucose levels, but they also require high levels of carbohydrates or glucagon to recover their blood glucose to normal levels. These individuals are also at far greater risk of severe hypoglycemia. While the exact cause of hypoglycemic unawareness is still under research, it is thought that these individuals progressively begin to develop fewer adrenergic-type symptoms, resulting in the loss of neuroglycopenic-type symptoms. Neuroglycopenic symptoms are caused by low glucose in the brain, and can result in tiredness, confusion, difficulty with speech, seizures, and loss of consciousness. Adrenergic symptoms are caused by the body's reaction to low glucose in the brain, and can result in fast heart rate, sweating, nervousness, and hunger. See section above on Signs and Symptoms for further explanation of neuroglycopenic symptoms and adrenergic symptoms.
Sources: en.wikipedia.org
=== Dietary supplement === In the United States, the extract for use in dietary supplements has self-affirmed generally recognized as safe (GRAS) status, as an ingredient. Supplemental use occurs in various forms, such as root powders, an additive in tea or coffee, and capsules alone or in combination with other ingredients. It is commonly used by bodybuilders or other sports participants in the belief the compound can increase testosterone levels that would improve performance. Available clinical research has found no significant effect of E. longifolia as a supplement. It is under preliminary research for erectile dysfunction, immunomodulation, and other effects. Side effects of using supplements may include nausea, abdominal discomfort, diarrhea, or headaches. Rare cases of liver injury have occurred from its use, mostly in bodybuilders. E. longifolia supplements should not be used during pregnancy. Its long-term safety over regular use has not been adequately assessed.
DNA expression requires the transfection of suitable host cells. Typically, either bacterial, yeast, insect, or mammalian cells (such as human embryonic kidney cells or Chinese hamster ovary cells) are used as host cells. Following transplantation into the host organism, the foreign DNA contained within the recombinant DNA construct may or may not be expressed. That is, the DNA may simply be replicated without expression, or it may be transcribed and translated and a recombinant protein is produced. Generally speaking, expression of a foreign gene requires restructuring the gene to include sequences that are required for producing an mRNA molecule that can be used by the host's translational apparatus (e.g. promoter, translational initiation signal, and transcriptional terminator). Specific changes to the host organism may be made to improve expression of the ectopic gene. In addition, changes may be needed to the coding sequences as well, to optimize translation, make the protein soluble, direct the recombinant protein to the proper cellular or extracellular location, and stabilize the protein from degradation.
Bremelanotide, another analogue of α-MSH, is available in the United States not as a photoprotective agent, but for the treatment of hypoactive sexual desire disorder in premenopausal women. All of these drugs have significantly greater potencies than α-MSH, along with improved pharmacokinetics and distinctive selectivity profiles.
"I had the original idea of how the machine would work and it was my patent, but it was a joint effort getting it to work in a saleable form. It was 3 years of very hard work. I had originally studied heavy electrical engineering before changing over to Medical School and qualifying as a Medical Doctor in 1968. In fact I was Senior House (Casualty) Officer (A&E or ER) in 1970 at North Manchester General Hospital when I filed the patent. I must have been the only hospital doctor in Britain with an oscilloscope, a soldering iron and a drawing board in his room in the Doctors' Residence. The housekeepers were bemused by all the wires. Frank originally trained as a Banker but quit to take a job with a local electronics firm during the development. He died in 1987, a terrible loss." [Extract from personal communication received in March 2010 from John Kirby.]
AAs = FFLLSSSSYY**CC*WLLLLPPPPHHQQRRRRIIIMTTTTNNKKSSRRVVVVAAAADDEEGGGG Starts = ---M---------------M---------------M---------------------------- Base1 = TTTTTTTTTTTTTTTTCCCCCCCCCCCCCCCCAAAAAAAAAAAAAAAAGGGGGGGGGGGGGGGG Base2 = TTTTCCCCAAAAGGGGTTTTCCCCAAAAGGGGTTTTCCCCAAAAGGGGTTTTCCCCAAAAGGGG Base3 = TCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAG
Sources: en.wikipedia.org
== Pharmacokinetics == Most wrinkle fillers are temporary because they are eventually metabolized by the body. Some people may need more than one injection to achieve the wrinkle-smoothing effect. The effect lasts for about six months. Results depend on health of the skin, skill of the health care provider, and the type of filler used. Regardless of material (whether synthetic or organic) filler duration is highly dependent on amount of activity in the body area where it is injected. Exercise and high intensity activities such as manual labor can stimulate blood flow and shorten the lifespan of fillers.
== Dosage forms == Alprazolam regular release and orally disintegrating tablets are available as 0.25 mg, 0.5 mg, 1 mg, and 2 mg tablets. Extended-release tablets are available as 0.5 mg, 1 mg, 2 mg, and 3 mg tablets. Liquid alprazolam is available in a 1 mg/mL oral concentrate.
=== A Loner (2020–2023) === The joint concert of Hangman's Chair and Regarde Les Hommes Tomber was due to be repeated at the Roadburn Festival 2020, but the performance ultimately did not take place. Chanut stated that Hangman's Chair recorded the album A Loner from December 2020 to January 2021, or, according to Thépegnier, until February 2021, with a view to an October release, but concert cancellations delayed it. Thépegnier indicated that the band's relationship with their former labels, Bones Brigade and Music Fear Satan, had always gone well. They had high expectations for Spinefarm Records, but ultimately, things did not go as planned. "Communication with Spinefarm has become very complicated", said Thépegnier. To amicably terminate their contract, Hangman's Chair initiated negotiations through their new manager. They were approached by the German and French offices of Nuclear Blast Records. The deal had accelerated after the opening of the French office because the band had already been in contact with the German office since This Is Not Supposed To Be Positive. Following their signing with Nuclear Blast Records, they released a new single titled "Cold & Distant" on 21 May 2021, accompanied by its music video featuring French actress Béatrice Dalle. Perturbator asked Hangman's Chair to collaborate on his song "God Says", from his 2021 album, Lustful Sacraments. Due to the coronavirus pandemic, the annual Hellfest could not take place, but a 15-minute live session from the band was made available on the festival's website in June 2021.
=== Lost Connections (2018) === Lost Connections was published in the US and UK on January 23rd, 2018. In Lost Connections, Hari argues that depression and related mental health conditions are not solely caused by chemical imbalances in the brain, instead being rooted in social, environmental, and psychological factors. Hari emphasizes that someone who finds benefits in taking an anti-depressant medication should not stop taking them. Kirkus Reviews praised Lost Connections. In one of The Guardian's reviews of the book, arts writer Fiona Sturges alluded to Hari's earlier examples of journalism malpractice that date to his earlier period as a newspaper reporter. She noted that in contrast, Hari made notes and interview recordings for Lost Connection available. Lost Connections has been translated into German, Japanese, and Spanish. The original UK and US releases of Lost Connections have different subtitles. The full title of the UK edition reads: Lost Connections: Why You're Depressed and How to Find Hope, while the US edition reads: Lost Connections: Uncovering the Real Causes of Depression - and the Unexpected Solutions.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.